Hydroquinone, once the most widely used skin-lightening ingredient in the world, has been banned or heavily restricted in dozens of countries because of concerns about cancer risk, a disfiguring skin condition called ochronosis, and an unusually high rate of absorption into the bloodstream. In the United States, over-the-counter hydroquinone products were pulled from shelves in September 2020. The European Union banned it from cosmetics even earlier. Here’s what drove those decisions.
What Changed in the U.S. in 2020
For decades, hydroquinone sat in a regulatory gray area. Products containing 2% or less were sold over the counter in drugstores across the country, while higher concentrations required a prescription. The FDA had flagged safety concerns as far back as 2006 but never finalized new rules.
That changed with the CARES Act, signed into law in March 2020. While the bill is best known for COVID-19 relief, it also overhauled how over-the-counter drugs are regulated. One consequence: OTC skin-lightening products containing hydroquinone were reclassified as “new drugs,” meaning they need formal FDA approval before they can be sold. No manufacturer had that approval, so effective September 23, 2020, all OTC hydroquinone products had to be removed from the market. Prescription hydroquinone, typically at 4% concentration and prescribed by a dermatologist for conditions like melasma, remains available in the U.S. under medical supervision.
The European Union took a harder line years earlier. Under its 2009 Cosmetics Regulation, hydroquinone is outright prohibited in cosmetic products. A recent surveillance study by the European network of cosmetics control laboratories found that 18% of skin-whitening products tested on the European market were non-compliant, containing banned substances including hydroquinone, mercury, or steroids. The ingredient circulates on the black and gray market in many countries despite formal bans.
It Absorbs Into the Body at Alarming Rates
Most topical skin care ingredients stay near the surface of the skin. Hydroquinone does not. Between 35% and 45% of the compound applied to the skin is absorbed systemically into the bloodstream. To put that in perspective, benzoyl peroxide is undetectable in the blood after topical use. Sunscreen ingredients like oxybenzone top out around 8.7%. Even glycolic acid, known for penetrating skin relatively well, absorbs at about 27%. Hydroquinone’s absorption rate is the highest of any common topical skin care ingredient.
That level of systemic exposure is the reason hydroquinone raises concerns that most topical products do not. When a compound stays on the skin’s surface, regulators worry mainly about local irritation. When roughly half of it enters the bloodstream, the questions shift to what it does inside the body over months or years of use.
Cancer Concerns From Animal Studies
The National Toxicology Program conducted two-year studies in which rats and mice were given hydroquinone orally. The results showed a pattern of increased tumor development across multiple species and sexes. Male rats developed kidney tumors at significantly higher rates than control animals. Female rats showed increased rates of leukemia, with cases rising in a dose-dependent pattern: the more hydroquinone they received, the more leukemia occurred. Female mice developed increased liver tumors, primarily benign adenomas.
The NTP concluded there was “some evidence of carcinogenic activity” in male rats, female rats, and female mice. That phrasing is deliberately cautious, falling short of “clear evidence,” but it was enough to raise red flags for regulators. These were oral studies, not topical ones, but given how much hydroquinone enters the bloodstream through the skin, the distinction matters less than it would for other ingredients.
A Skin Condition Worse Than the Problem It Treats
The most visible risk of long-term hydroquinone use is exogenous ochronosis, a condition where the skin develops blue-black or gray-blue patches that are often permanent and extremely difficult to treat. It is, ironically, a form of hyperpigmentation caused by a product meant to reduce hyperpigmentation.
Ochronosis develops when hydroquinone penetrates past the outer skin layers into the deeper dermis. There, it interferes with an enzyme that normally breaks down a substance called homogentisic acid. When that enzyme is blocked, homogentisic acid and its byproducts accumulate and bind to collagen and elastic fibers, forming yellowish-brown deposits that appear as dark discoloration on the skin’s surface. The patches typically appear in sun-exposed areas, especially the cheeks, temples, and neck, in a symmetrical pattern. In advanced cases, small raised bumps described as “caviar-like” develop on the affected skin.
Ochronosis is most commonly reported in people with darker skin tones who use hydroquinone-containing products for extended periods. It is not reversible with standard treatments, and in many cases the disfigurement is permanent.
How Hydroquinone Damages Skin Cells
Hydroquinone lightens skin by targeting melanocytes, the cells responsible for producing pigment. It works partly by blocking an enzyme involved in pigment production, but the damage goes further than that. Inside melanocytes, hydroquinone is converted into a highly reactive compound called quinone, which is directly toxic to the cells. Over time, this doesn’t just reduce pigment production. It destroys the melanocytes themselves.
Research using electron microscopy has shown that hydroquinone alters how melanocytes form their pigment-producing structures, disrupting both the creation and breakdown of melanin at a cellular level. This destructive mechanism is what makes hydroquinone effective as a bleaching agent, but it’s also why the effects can become unpredictable and harmful with prolonged use. Destroying melanocytes unevenly across the skin can lead to patchy, irregular pigmentation that looks worse than the original condition.
Alternatives for Treating Dark Spots
Several ingredients have demonstrated effectiveness for hyperpigmentation without the safety profile that got hydroquinone restricted. Azelaic acid, derived from grains like wheat and barley, is one of the most studied. It’s available over the counter at lower concentrations and by prescription at higher ones. Vitamin C (ascorbic acid) and niacinamide, a form of vitamin B3, both have clinical evidence supporting their use for evening skin tone.
Other options with research backing include kojic acid (derived from fungi used in fermentation), licorice extract, arbutin (a plant-derived compound), and soy-based formulations. Green tea extract, turmeric, and ellagic acid have also shown depigmenting effects in studies, though evidence varies. None of these alternatives works as quickly or as aggressively as hydroquinone, which is part of why some people still seek it out despite the ban. But none of them carry the risk of ochronosis, systemic toxicity, or the cancer signals that made regulators act.
For persistent or severe hyperpigmentation like melasma, prescription-strength treatments remain available through a dermatologist. In the U.S., this can still include hydroquinone at 4% concentration when a doctor determines the benefits outweigh the risks for a specific patient, used for a limited period under monitoring.